What is Lucence?
Founded in 2016 and headquartered in Singapore, Lucence is at the forefront of precision oncology. The company specializes in creating sophisticated liquid biopsy blood tests. These tests are designed to analyze a patient's molecular profile, thereby identifying the most effective cancer treatments. This approach aims to revolutionize cancer care by offering a more targeted and personalized therapeutic strategy.
How much funding has Lucence raised?
Lucence has raised a total of $20M across 1 funding round:
Series A
$20M
Series A (2019): $20M with participation from SGInnovate, Lim Kaling, IHH Healthcare, Heliconia Capital, and Koh Boon Hwee
Key Investors in Lucence
SGInnovate
SGInnovate is a Singaporean entity focused on nurturing the Deep Tech landscape through investment and talent development, supporting companies in the sector.
Lim Kaling
An individual investor participating in the funding round.
IHH Healthcare
IHH Healthcare is a major healthcare provider, likely investing to enhance diagnostic capabilities within its network.
What's next for Lucence?
The recent major strategic investment signals a pivotal growth phase for Lucence, likely enabling the company to scale its operations, further refine its liquid biopsy technology, and expand its market reach. This substantial backing suggests confidence from investors in Lucence's innovative approach to cancer diagnostics and treatment selection, positioning the company for accelerated development and potential market leadership in the precision oncology sector.
See full Lucence company page
